Path ID: DB00820_MESH_D011470_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000068581 | tadalafil | Drug |
| UniProt:O76074 | cGMP-specific 3’,5’-cyclic phosphodiesterase | Protein |
| GO:0046069 | cGMP catabolic process | BiologicalProcess |
| CHEBI:16356 | 3’,5’-cyclic GMP | ChemicalSubstance |
| GO:0007263 | nitric oxide mediated signal transduction | BiologicalProcess |
| GO:0044557 | relaxation of smooth muscle | BiologicalProcess |
| HP:0011037 | Decreased urine output | PhenotypicFeature |
| MESH:D011470 | Benign prostatic hyperplasia | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Tadalafil | DECREASES ACTIVITY OF | Cgmp-Specific 3’,5’-Cyclic Phosphodiesterase |
| Cgmp-Specific 3’,5’-Cyclic Phosphodiesterase | POSITIVELY REGULATES | Cgmp Catabolic Process |
| Cgmp Catabolic Process | DECREASES ABUNDANCE OF | 3’,5’-Cyclic Gmp |
| 3’,5’-Cyclic Gmp | POSITIVELY CORRELATED WITH | Nitric Oxide Mediated Signal Transduction |
| Nitric Oxide Mediated Signal Transduction | POSITIVELY CORRELATED WITH | Relaxation Of Smooth Muscle |
| Relaxation Of Smooth Muscle | NEGATIVELY CORRELATED WITH | Decreased Urine Output |
| Decreased Urine Output | MANIFESTATION OF | Benign Prostatic Hyperplasia |
Comment: The drug is beneficial for the treatment of benign prostatic hyperplasia symptoms such as difficulty with urination.
Reference: